Navigation Links
VIVUS Announces New Qsymia Offer
Date:3/5/2013

ref="http://www.qsymia.com/">www.qsymia.com.

* Based on the full retail price of 30 capsules of Qsymia 7.5 mg/46 mg ($85 savings), and the full retail price of 14 capsules of the Qsymia starting dose, 3.75 mg/23 mg ($65 savings), for a total of $150.

About Qsymia
Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information
Qsymia (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomn
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sequenom Announces Participation At The Barclays Global Healthcare Conference
2. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
3. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
4. SI-BONE, Inc. Announces Spring Society Meeting Attendance
5. Relmada Therapeutics Announces LevoCap ER Development Progress
6. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
7. Evofem Announces Strategic Alliance with WomanCare Global
8. DMH International Announces Agreement with MyDICOM and ChangZhou Wealth Information & Technology Co. Ltd
9. Hill-Rom Announces Second Quarter 2013 Dividend
10. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
11. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Stem Cell Research Products: Opportunities, Tools & Technologies" ... already supply stem cell research products or you wish ... essential and lucrative this market is. The authors know ... sell more effectively to scientists, to generate improved revenues ...
(Date:8/22/2014)... CHICAGO , Aug. 22, 2014   Zacks Equity Research ... the Bull of the Day and Panera (Nasdaq: PNRA - ... Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD ... ) and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The ...
(Date:8/22/2014)... 2014  - MediaLINC ... Today Lincor announced general availability of MediaLINC ... a range of education, entertainment and clinical content direct ... http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor has ... patient engagement to bedside smart devices, " comments ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... QTinno(TM) - proves the ability to automatically measure QT ... intervals in even challenging samples, ... Board: NWCI) a cardiac diagnostic and services company, today,revealed the ... Study"). The study was led by an independent industry leading,cardiac ...
... Battles Highest Rate of TB Infection in U.S., ... highest,rate of tuberculosis (TB) in the U.S., with recurrent ... most recent study on,homelessness and TB by Harvard Medical ... in San Francisco. To address this health care,crisis, St. ...
Cached Medicine Technology:NewCardio Announces Positive Results From Third Clinical Validation Study 2NewCardio Announces Positive Results From Third Clinical Validation Study 3NewCardio Announces Positive Results From Third Clinical Validation Study 4NewCardio Announces Positive Results From Third Clinical Validation Study 5National Healthcare for Homeless Day: August 13th, 2008 2
(Date:8/22/2014)... UT (PRWEB) August 22, 2014 Today, ... a new guide on Account-Based Health Plans. , According ... (ABHPs) as a strategy to lower the cost of ... types of medical spending accounts, however, can be confusing. ... chart to learn the four main types of ABHPs. ...
(Date:8/22/2014)... August 23, 2014 Top 10 ... famous web hosting companies and highly recommended FatCow ... , The manager of Top 10 Best SEO ... good dedicated server hosting supplier. Actually, these companies ... server speed and customer support. People can get ...
(Date:8/22/2014)... Recently, UWDress.com, a leading online supplier of ... new range of empire bridesmaid dresses to its ... a summer promotion for these high quality items. All of ... to 75 percent off. , The company’s new items ... efficient assistance on its website. It is true that all ...
(Date:8/22/2014)... 2014 Buying a policy for different life ... unsure about available coverage types by insurers in the U.S. ... policy pricing to the public using its sortable tool at ... is free and is expected to promote the discounts and ... throughout the U.S. The system is designed to help an ...
(Date:8/22/2014)... Japantown Dental is excited to announce that ... Air polishing is a technique used to remove external ... be caused by a number of factors, which are ... External stains include coffee, wine, tea, smoking and chewing ... such as tetracycline, and direct trauma to the tooth. ...
Breaking Medicine News(10 mins):Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Japantown Dental Introduces Air Polishing 2
... ROCHESTER, N.Y., Nov. 26 As one of the ... considering the most sweeping,changes to that state,s health care ... the Christian Science church, called on,state leaders to bring ... access to effective health care by including spiritual,care., ...
... The Wackenhut,Corporation, the leading security services provider, announced ... its employee medical and dental,insurance plans significantly for ... that Wackenhut,s focus on employee welfare is a,primary ... Mercer, released an overview of,its most recent annual ...
... FLEX ),today announced that it will report third quarter ... call, hosted by Flextronics,s senior,management, will be held at ... Company for its third quarter ended December 31, 2007., ... Internet and may be,accessed by logging on to the ...
... with the devices aren,t prone to accidents , , MONDAY, ... implanted in people for instant correction of abnormal heartbeats ... researchers report. , "What this confirms is what we ... risk in this population," said study lead author Dr. ...
... Agreement will Broaden Access to ... Cholesterol-Reducing Medicine, PHILADELPHIA and ... and Merck & Co., Inc.,Whitehouse Station, NJ, USA (Merck), announced ... marketing rights for,MEVACOR(R) (lovastatin). Under the agreement, GSK will have ...
... Older and newer medicine together often bring relief, study ... an older synthetic drug with a newer, "biologic" medication ... tenderness of rheumatoid arthritis, a new study finds. , ... newer drugs are not better than older ones when ...
Cached Medicine News:Health News:Wackenhut Enhances Health Insurance Plans Without Raising Costs 2Health News:Flextronics to Report Third Quarter Results 2Health News:Defibrillators Not Dangerous While Driving 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 4Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 5Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 6Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 7Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 8Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 9Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 10Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 11Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 12Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 13Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 14Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 15Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 16Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 17Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 18Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 19Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 20Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 21Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 22Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 23Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 24Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 25Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 26Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 27Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 28Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 29Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 30Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 31Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 32Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 33
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: